Investments · Pharmaceuticals (generics)
Sumitomo Corp. takes minority stake in Sawai's US generics business
- Investor
- Sumitomo Corporation (Tokyo)
- In
- Sawai Pharmaceutical's US subsidiary (parent of Upsher-Smith), Maple Grove, Minnesota
- Value
- ¥23.2B
- Status
- Completed in 2017.
- Date
- 2017-11-13
Sumitomo Corporation bought a partial interest in Sawai Pharmaceutical's US subsidiary, which owns the Minnesota generic drug maker Upsher-Smith Laboratories, for ¥23.2 billion. Both buyer and seller are Japanese, but the asset is a US business that Sawai bought earlier in 2017.
Why it matters
The stake lets Sawai share the cost of its large US purchase with a trading house that brings its own healthcare business experience.
Sources
Kakehashi M&A News home
